Biopharma companies develop medicines, vaccines and advanced therapies to prevent, treat and manage disease. The sector spans drug discovery, clinical development, manufacturing and commercialisation across a wide range of therapeutic areas.
This category includes companies working on:
Browse 304 UK biopharma companies below.
Small molecule drugs targeting intrinsically disordered proteins in cancer
Kodiform Therapeutics is a drug discovery company developing first-in-class small molecule inhibitors against intrinsically disordered protein targets in cancer, a class historically considered undruggable due to the absence of stable binding pockets. The company uses intracellular antibody technology to identify and…
Novel ADC payloads targeting NMT enzymes in cancer
Myricx Bio is a clinical-stage biotechnology company developing a novel class of antibody-drug conjugate payloads based on inhibition of N-myristoyltransferase, an enzyme essential to cancer cell survival. Its NMTi payload chemistry platform addresses limitations of existing ADC payloads, including resistance and…
Oral small-molecule therapies targeting autoimmune disease pathways
SMIN Therapeutics is a biotechnology company developing oral medicines for autoimmune diseases. Its drug discovery platform studies interactions between proteins to identify therapeutic compounds, with an initial focus on the neonatal Fc receptor (FcRn), which regulates immunoglobulin G (IgG). The company is…
AI-enabled small molecule drug discovery
PharmEnable is a Cambridge-based drug discovery company developing novel small molecule therapeutics for targets that are inaccessible to biologics, including intracellular targets and those behind the blood-brain barrier. Its proprietary platform integrates AI and advanced medicinal chemistry to explore undercharted…
Specialist vaccine development and GMP manufacturing in Scotland
Valneva Scotland Limited is the UK manufacturing and R&D subsidiary of Valneva SE, a specialty vaccine company. Operating from an MHRA-authorised GMP facility in Livingston, the site produces commercial and pipeline vaccines including IXCHIQ, the world's first approved chikungunya vaccine, and IXIARO for Japanese…
Small molecule theranostics to improve transplant outcomes
Kairos Biotech is an early-stage biotechnology company developing proprietary small molecules and nanoscale-engineered binders for application in transplant diagnostics and targeted immunotherapy. The company's theranostic approach identifies molecules capable of detecting donor-specific alloreactivity and further…
AI-driven natural product discovery for neurological therapeutics
Pangea Bio is a clinical-stage biotechnology company developing small molecule therapeutics for neurological and neuropsychiatric disorders. Its proprietary AI platform screens natural and plant-derived chemical space, integrating ethnobotanical data with machine learning to identify novel CNS drug candidates with…
Defined live bacterial consortia for oncology and inflammatory bowel disease
Microbiotica is a clinical-stage biopharmaceutical company developing oral live biotherapeutic products comprising defined consortia of gut commensal bacterial strains. Candidate bacterial strains are identified by analysing microbiome data from clinical outcome studies, enabling mechanistically grounded strain…
Computational cell models for novel drug target discovery
Oppilotech is a UK biotechnology company that uses systems biology and machine learning to build high-resolution computational models of cells and bacteria. Its proprietary platform simulates biochemical pathways to identify viable drug targets and generate first-in-class discovery programmes. The company's primary…
Generic, branded and biosimilar medicines across global therapeutic areas
Viatris UK Healthcare is the UK subsidiary of Viatris Inc., a global pharmaceutical company formed in 2020 through the combination of Mylan and Pfizer's Upjohn division. Operating from sites in Hertfordshire, Cambridge, and Sandwich, Kent, the UK entity carries out formulation and device research and development,…
Protein superglue vaccine platform targeting infectious disease and cancer
SpyBiotech is a clinical-stage biotechnology company developing vaccines using its proprietary protein superglue technology, which enables efficient and stable attachment of antigens to virus-like particle and viral vector delivery platforms. The approach improves immunogenicity and reduces manufacturing complexity…
Global influenza vaccine leader with major UK manufacturing in Liverpool
CSL Seqirus is one of the world's largest influenza vaccine companies, operating the only injectable influenza vaccine manufacturing facility in the UK at Speke, Liverpool. The site employs more than 650 people and produces egg-based and cell culture-derived influenza vaccines for seasonal and pandemic use, with surge…
Ion channel drug discovery platform for rare CNS disorders
Autifony Therapeutics is a clinical-stage UK biotech developing small molecule modulators of Kv3 voltage-gated potassium channels for rare genetic CNS disorders. Lead programmes target Fragile X syndrome and rare myoclonic epilepsy syndromes, with preclinical work extending to schizophrenia, hearing loss, and…
Transcription factor-targeting drug discovery for neurodegeneration
Scripta Therapeutics is an Oxford-based biotech company developing disease-modifying therapeutics by mapping and modulating transcription factor networks. Its platform integrates AI, imaging, and patient-derived models in a lab-in-the-loop workflow to identify compounds that restore healthy cellular states. The…
VHH single-domain antibody therapeutics for companion animals and livestock
272Bio is a biotechnology company developing biotherapeutic treatments for animal health applications across livestock and companion animals. The company applies novel antibody engineering technologies, including VHH-based biologics, to create targeted and cost-effective therapies for veterinary diseases. 272Bio…
Veterinary pharmaceuticals developed and manufactured in Northern Ireland
Norbrook Laboratories is a vertically integrated veterinary pharmaceutical company developing, manufacturing and distributing medicines for farm and companion animals. Operating from three GMP-certified sites in Newry, the company produces a portfolio spanning injectables, tablets, pour-ons and oral solutions,…
Dark genome platform identifying first-in-class targets for autoimmune disease
Nucleome Therapeutics is a drug discovery company using 3D genome mapping to identify therapeutic targets encoded in the non-coding regions of the human genome. Its platform integrates high-resolution chromatin conformation data with functional genomics and machine learning to link disease-associated genetic variants…
Antibody immunotherapy targeting toxic tau for neurodegenerative disease
TauC3 Biologics is a preclinical biopharmaceutical company developing an antibody-based immunotherapy that targets tauC3, a toxic, truncated form of the tau protein implicated in neurodegenerative disease. Its lead candidate, TBL-100, is a humanized monoclonal antibody developed with LifeArc, designed to selectively…
Infant gut bacteria-derived therapeutic compounds
Bioscopic is a UK biotech developing therapeutic compounds derived from infant gut bacteria to treat cancer and chronic disease. It holds what it describes as the world's largest collection of infant gut bacterial strains, which it uses as a screening platform to identify biologically active compounds. Its lead…
Clinical-stage company developing treatments for cancer cachexia and muscle wasting
Actimed Therapeutics is a clinical-stage specialty pharma developing treatments for cancer cachexia and muscle wasting disorders, areas with significant unmet need and no globally approved therapies. Its lead programme has completed Phase 1 and received FDA IND approval, with a Phase 2b/3 trial planned in non-small…